建科股份分析师会议 调研日期：2025年05月20日 调研行业：专业服务 参与调研的机构：上海曜与基金、上海贵源投资、上海璞智投 资、杭州月阑私募、深圳盈富汇智私募等 / | Gallia | | | --- | --- | | 11 2 12 200 2 110 | | | 1:给我们 = 影片面临官 = | | | 阿里巴巴佩尼 | | | 钢铁机之题。 8 | 图纸制图: 23 | | 20GB Millio Aller 19 | | | 海双集团 | | | 1 1 80.0 0 | 总机构建 23 | | LOGA: REGH, KETA: 1986 | | | 小麦具日 | | | 的研究次数:8 | 上机构馆:23 | | 定年代的:用者点击:我要的中:主要原因 | | | START SHILL CARD | | | 颜的集团 | | | 例体位次数 4 | 24/40 33 | | FININ EXIAN, BENN, LEWI | | | 極力集团 | | | · 例计以上的 8 | 品机构管 23 | 调研基本情况 调研对象：建科股份 所属行业：专业服务 接待时间：2025-05-20 ...

Group 1 - The core point of the news is that Zhaoyi Innovation plans to issue H-shares for overseas listing on the Hong Kong Stock Exchange to enhance its global strategy and brand image, with a maximum issuance of 10% of the total share capital post-issuance [1] - The funds raised from the listing will be used to strengthen R&D capabilities, continue product and technology innovation, strategic investments and acquisitions, and global marketing and business network development [1] - Following the announcement, Zhaoyi Innovation's A-shares experienced a decline of over 6%, resulting in a total market capitalization of 78.6 billion yuan [1] Group 2 - In Q1 2024, Zhaoyi Innovation reported revenue of 1.909 billion yuan, a year-on-year increase of 17.32%, and a net profit attributable to shareholders of 235 million yuan, up 14.57% [2] - As of March 31, 2025, Zhaoyi Innovation had a strong cash reserve of 9.409 billion yuan in monetary funds and 100 million yuan in trading financial assets, with short-term borrowings of 970 million yuan and no long-term borrowings or payable bonds [2] Group 3 - Other semiconductor companies such as Jiangbolong, Naxinwei, and Jiehuate have also announced plans for listing in Hong Kong, indicating a trend of semiconductor firms seeking international expansion amid technological and geopolitical challenges [3] - The "A+H" listing model provides an efficient platform for international capital operations, allowing companies to access a more diversified international capital base [3] - According to CITIC Securities, a wave of A-share companies is expected to seek Hong Kong listings starting in the second half of 2025, with a significant increase in the number of companies disclosing plans for Hong Kong listings in April 2025 alone [3]

Group 1: Company Strategy and Transformation - The company has transitioned from "建科股份" to "联检科技," reflecting a redefined vision and commitment to integrated inspection and testing services [3] - The mission is to empower quality ecosystems through technology, focusing on sustainable development and innovation [3] - The internationalization strategy includes three phases: initial focus on "Belt and Road" initiatives, mid-term technical reciprocity with Europe and the U.S., and long-term global network collaboration [3] Group 2: Business Performance and Market Position - The company has experienced pressure on net profit due to the slowdown in real estate and infrastructure investments, prompting a strategic shift towards emerging sectors [2] - Recent acquisitions have expanded capabilities in electronic, automotive, and food testing sectors, enhancing overall business performance [2][4] - The company aims to maintain a core focus on inspection and testing while diversifying through mergers and acquisitions to improve competitiveness [4] Group 3: Technological Innovation and Development - The company is investing in digitalization and smart technologies to enhance service efficiency and quality, including the development of AI and IoT applications [6][9] - A digital twin integrated platform has been established to create a comprehensive safety monitoring system [6] - The company is actively pursuing R&D collaborations to drive innovation in emerging technologies, particularly in synthetic biology and medical data [9] Group 4: Market Expansion and Future Growth - The company is expanding its market presence beyond Jiangsu, with operations established in Vietnam, Thailand, Indonesia, and the UAE [2][3] - Future growth will be driven by focusing on high-value sectors such as renewable energy, electronics, and automotive components [4][8] - The establishment of an industry fund aims to support investments in inspection and testing projects, as well as new energy and smart manufacturing sectors [8] Group 5: Competitive Strategy and Industry Trends - The company adopts a dual strategy of internal growth and investment mergers to enhance market coverage and technical capabilities [7] - The trend towards industry consolidation presents opportunities for the company to increase market share and improve operational efficiency [8] - The company is addressing competitive challenges by enhancing its technological strength and expanding its international market footprint [7][8]

Group 1: Company Overview and Competitive Advantages - The company focuses on carbon fiber products for the lightweight and high-end applications in the new energy vehicle industry, providing a one-stop service from structural design to mass production [2][3] - Key products include front hoods, trunk lids, automatic tail wings, side skirts, and various interior and exterior functional components [3] - The company leverages its technology in composite material molding and has developed unique advantages in carbon fiber paint technology and high-quality appearance processes [3] Group 2: Expansion and Production Capacity - The company plans to expand its production base in Thailand to meet the growing demand in Southeast Asia, enhancing local delivery efficiency for new energy vehicles and smart home appliances [4] - The expansion will involve the purchase of high-end equipment and the establishment of intelligent production lines, creating a one-stop production capability from modified plastics to plastic products [4] Group 3: Future Strategic Planning - The company aims to capitalize on the domestic industry's transformation and the high-end, lightweight development of new energy vehicles by optimizing resource allocation and increasing R&D investment [5] - By 2024, the company expects to achieve mass production of high-performance and lightweight carbon fiber products while expanding into international markets [5][6] - The focus will remain on three core product lines: high-performance modified plastics, precision molded products, and high-performance carbon fiber products, with an emphasis on emerging fields such as flying cars and robotics [5][6]

[Table_Title] 研究报告 Research Report 19 May 2025 [Table_header2] 奇德新材 (300995 CH) APPENDIX 1 Summary 奇德新材 Guangdong Kitech New Material (300995 CH) 高分子复合改性材料领军企业，碳纤维制品发展空间广阔 Polymer composite modified materials leader, accelerating international layout 孙小涵 Xiaohan Sun xh.sun@htisec.com [Table_yemei1] 热点速评 Flash Analysis [Table_summary] (Please see APPENDIX 1 for English summary) [Table_yejiao1] 本研究报告由海通国际分销，海通国际是由海通国际研究有限公司，海通证券印度私人有限公司，海通国际株式会社和海通国 际证券集团其他各成员单位的证券研究团队所组成的全球品牌，海通国际证券集团各成员分别在其许可的司法管辖区内从事证 券活动。 ...

Core Viewpoint - The engineering machinery industry is experiencing a recovery driven by innovation and green transformation, with a focus on high-quality development and international competitiveness [3][4][5][7]. Group 1: Global Opportunities and Challenges - The global economy is steadily recovering amidst multiple challenges, with emerging markets in Asia being the main growth drivers. The IMF predicts a global growth rate of 2.8% in 2025, while infrastructure demand along the Belt and Road Initiative is invigorating the industry [3]. - The Chinese engineering machinery sector is showing positive trends, with significant growth in export trade during the first quarter, indicating a strong recovery signal [3]. Group 2: Green Transformation - The electrification rate of high-altitude work platforms in China has exceeded 90%, with rapid "oil-to-electric" transitions in products like forklifts and loaders. A peak in electric product sales is expected in 2025 [4]. - The company is focusing on pure electric technology and has introduced hybrid products that save 30% to 50% in energy consumption, while also establishing zero-emission factories [4]. Group 3: Internationalization Strategy - The rapid growth of Chinese engineering machinery exports reflects industrial upgrades. However, companies need to shift from price competition to value competition by enhancing brand value through technological reliability and standardized services [5]. - To mitigate international risks such as exchange rate fluctuations and legal compliance, the company advocates for diversified layouts, financial hedging tools, and strengthened compliance management [5]. Group 4: Collaborative Ecosystem - To address issues like price wars and overcapacity, the industry should build a "symbiotic win-win" ecosystem. It is suggested that the China Construction Machinery Industry Association establish minimum price standards for overseas markets to curb disorderly competition [6]. - Companies are encouraged to explore niche markets and develop new models such as leasing and second-hand remanufacturing [6]. Group 5: Sustainable Development - The engineering machinery industry is moving towards high-quality development through innovation and collaboration. The company aims to contribute sustainable solutions to global infrastructure by fostering a collaborative research and development ecosystem [7]. - The focus is on transitioning from zero-sum games to symbiotic win-win scenarios, establishing a sustainable global industrial landscape [7].

Group 1 - The A-share market saw a collective decline on May 16, while the Sci-Tech Innovation Pharmaceutical sector rebounded, with the Sci-Tech Innovation Pharmaceutical ETF (588860) rising by 0.16% [1] - Notable stocks in the sector included Maiwei Biotech-U, which increased by over 5%, along with Shouyao Holdings-U, KQ Biotech, Innotec, CanSino, and Baotai, all of which experienced gains [1] - The Sci-Tech Innovation Pharmaceutical ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which selects 50 large-cap companies in biopharmaceuticals and related fields to reflect the overall performance of representative companies in the sector [1] Group 2 - According to CMB International, the optimization of centralized procurement policies in mainland China provides hospitals and enterprises with more flexibility and autonomy, benefiting leading prescription drug companies [2] - The anticipated implementation of favorable policies, such as the 2025H2 medical insurance category, is expected to accelerate industry consolidation, with the sector's valuations remaining at historical lows [2] - The recommendation is to focus on innovative drug targets with high growth potential or clear breakeven timelines after short-term sentiment stabilizes [2]

Core Viewpoint - The People's Bank of China announced a comprehensive reduction in the reserve requirement ratio by 0.5 percentage points and a simultaneous cut in policy interest rates, releasing approximately 1 trillion yuan in long-term liquidity, indicating a further tilt towards "moderately loose" monetary policy [1] Group 1: Policy Impact on the Reinsurance Industry - The policy combination injects momentum into the real economy and reshapes the financial market landscape through interest rate transmission mechanisms [1] - The low interest rate environment accelerates the restructuring of the risk pricing system in the reinsurance industry, compelling firms to enhance risk management capabilities and product innovation efficiency [1] - China Reinsurance, as a leading player in the domestic reinsurance sector, demonstrates significant competitive advantages, benefiting from its scale and core participation in the Shanghai International Reinsurance Center [1][2] Group 2: Financial Performance of China Reinsurance - In the first quarter of 2025, China Reinsurance reported a net profit of 3.508 billion yuan, a year-on-year increase of 155.3%, with notable growth in various segments [2] - The net profit of China Re Property & Casualty Insurance increased by 21.3% to 626 million yuan, while China Re Life Insurance saw a staggering growth of 537.2% to 1.147 billion yuan [2] Group 3: Asset-Liability Management - The 1 trillion yuan released by the reserve requirement cut enhances market liquidity and instills confidence in long-term capital entering the market [3] - The reduction in policy interest rates aims to lower financing costs, benefiting both enterprises and households, thereby stimulating economic growth and consumer spending [4] Group 4: Structural Opportunities in the Insurance Sector - The ongoing decline in liability costs creates a favorable operating environment for insurance companies, enhancing the price competitiveness of traditional life insurance products [5] - Insurers are increasingly utilizing proportional reinsurance to reduce capital occupation and enhance underwriting capacity, creating a positive feedback loop [5] Group 5: Strategic Advantages of China Reinsurance - China Reinsurance's core competitiveness is rooted in its three-dimensional strategic framework of risk management, technological empowerment, and internationalization [8] - The company has developed proprietary catastrophe models and innovative insurance products, positioning itself as a leader in catastrophe insurance projects across multiple provinces [8][9] - The digital transformation strategy initiated in 2018 has enabled China Reinsurance to enhance operational efficiency and drive business innovation [9] Group 6: International Expansion and Risk Diversification - By the end of 2024, international business accounted for nearly 20% of China Reinsurance's operations, with overseas assets making up about 25% [10] - The company's global presence across 11 countries and regions allows it to effectively hedge against regional risk shocks [10] Group 7: Future Growth Prospects - The dual drivers of policy benefits and market expansion are expected to accelerate the beta effect in the industry, optimizing capital costs and asset allocation efficiency for insurers [11] - China Reinsurance is positioned to leverage a combination of low-cost financing and high-yield assets to further enhance investment momentum [11] - The long-term growth logic of the industry will be anchored in technology, globalization, and green finance, allowing China Reinsurance to capture emerging market opportunities [11][12]

Group 1 - The core viewpoint of the article highlights the rise of Mindray Medical as a symbol of the Shenzhen medical device industry's transformation from non-existence to a global leader in medical devices and solutions [1] - Mindray Medical has significantly impacted the supply chain by promoting the localization of core components, with over 80% of its first-tier suppliers being domestic, and collaborating with more than 1,500 suppliers across various sectors [1] - During the surge in demand for ventilators in 2020, Mindray Medical increased its procurement of domestic components and worked closely with suppliers to enhance production capacity and establish quality control standards [1] Group 2 - Mindray Medical is driving the high-end standardization of domestic medical devices, with a reputation for rigorous quality testing, which has elevated the quality control standards across the industry [2] - The company's products are now available in over 190 countries, with a market share in the top three for key products like monitors, anesthesia machines, and ventilators, and international revenue contributing approximately 45% of total income [2] - Mindray Medical's internationalization strategy includes utilizing local talent, with nearly 80% of overseas key employees required to regularly visit the Shenzhen headquarters for knowledge exchange [3] Group 3 - The company has established a robust overseas talent management system, integrating local knowledge with its corporate culture to enhance cohesion and operational effectiveness [3] - Over 90% of Mindray Medical's 3,000 overseas employees are local hires, demonstrating the company's commitment to local integration in global markets [3]

几乎是"平价"发行 宁德时代本次赴港上市可谓是极为迅速，从申报到正式上市仅用时三个多月。宁德时代在今年2月11日正式递表港交所，并于3月25日获得中国证监会出具 的境外发行上市备案通知书，4月11日通过港交所聆讯。5月12日开始招股，预计在5月20日上市。 在宁德时代本次初步发售安排中，绝大部分份额都给到了机构投资者，公开发售份额仅占7.5%。 自5月12日开启招股以来，宁德时代在港股IPO的认购热情持续火爆。 富途牛牛数据显示，截至5月15日，宁德时代的公众认购倍数已超过120倍，融资申购额已经超过2822亿港元。 而对于机构的申购情况，宁德时代的一家保荐机构人士告诉证券时报记者："宁德时代的申购情况非常火爆，我们现在每天都要加班到凌晨2点，加上超额 配售和绿鞋机制，本次宁德时代的募资规模会非常大。" 宁德时代计划于5月20日正式在港交所主板挂牌交易。若按每股最高发行价263.00港元计算，本次H股IPO募资规模预计在310亿港元左右，若算上1770万 股的额外授权发售以及1770万股的绿鞋期权，宁德时代此次的募资额有望扩大至410亿港元。 这或将让宁德时代成为近年来港股市场规模最大的IPO项目。同时也或将 ...